Nonsteroidal anti-inflammatory drugs (NSAIDs) represent one of the most widely prescribed and over-the-counter drug categories worldwide. They are integral to the management of pain, inflammation, and fever in medical specialties such as rheumatology, orthopedics, neurology, and general practice. Despite their clinical utility, prolonged or inappropriate use of NSAIDs is associated with a spectrum of gastrointestinal (GI) toxicities, ranging from mild gastritis to severe peptic ulcer disease and life-threatening bleeding or perforation. This paper explores the mechanisms, epidemiological burden, and prevention of NSAID-induced gastrointestinal ulcer disease.

Lanas A, Chan FKL. Peptic ulcer disease. Lancet. 2017;390(10094):613–624.

Cryer B, Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used NSAIDs. Am J Med. 1998;104(5):413–421.

Wallace JL. Mechanisms, prevention and clinical implications of NSAID-enteropathy. World J Gastroenterol. 2013;19(12):1861–1876.

Bhatt DL et al. Expert consensus on reducing GI risks of antiplatelet therapy and NSAID use. J Am Coll Cardiol. 2008;52(18):1502–1517.

Lichtenberger LM, Zhou Y, Jayaraman V. NSAID injury to the GI tract: evidence, mechanisms, and prevention. Curr Opin Gastroenterol. 2022;38(6):589–597.

Yeomans ND. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs: New insights and preventive strategies. Med J Aust. 2019;210(3):106–111.

Scheiman JM, Fendrick AM. Summing the risk of NSAID therapy. Lancet. 2007;369(9573):1580–1581.

Scarpignato C et al. Safe prescribing of NSAIDs: A consensus statement. Dig Liver Dis. 2018;50(9):991–1001.

Oybekovich, L. O. (2025). GLOSSITIS: UNDERSTANDING THE INFLAMMATION OF THE TONGUE. International Journal of Cognitive Neuroscience and Psychology, 3(9), 72–74.